AHA Scientific Sessions 2024 Late-Breaking and Featured Science Collection
Published: 29 October 2024
-
Views:
2109
-
Likes:
7
-
Views:
2109
-
Likes:
7
-
Up Next -
4m 30sPart 3 | Session 9 ENDEAVOR: Myeloperoxidase Inhibition with Mitiperstat in HFpEF -
3m 49s -
5m 28sPart 3 | Session 11 ALPACAR: Phase 2 Trial of Zerlasiran in High Risk Patients -
3m 44sPart 3 | Session 12 BROOKLYN: Safety and Efficacy of Obicetrapib in Patients with HeFH -
3m 40sPart 3 | Session 13 KRAKEN: Phase 2 Trial of Muvalaplin in High Risk Patients -
5m 15sPart 3 | Session 14 OPTION: LAA Closure with Oral Anticoagulation after AF Ablation
-
13m 43sPart 1 View from the Thoraxcenter: AHA 24 Late-breaking Preview Joost Daemen, Nicolas M Van Mieghem
-
29m 32sPart 2 | Session 1 ZODIAC: Decision Support System to Aid Optimization of Early Lipid Lowering Therapies After ACS Harriette Van Spall, Kausik Ray
-
18m 41sPart 2 | Session 2 NUDGE-FLU: Electronic Nudges to Increase Influenza Vaccination in Patients with MI Harriette Van Spall, Tor Biering-Sørensen
-
17m 22sPart 2 | Session 3 SUMMIT: Tirzepatide in Patients with HFpEF and Obesity Harriette Van Spall, Milton Packer
-
16m 57sPart 2 | Session 4 FLOW: Benefits of Semaglutide on CKD by Cardiovascular Status or Risk Harriette Van Spall, Katherine Tuttle
-
22m 30sPart 2 | Session 5 REALIZE-K: Efficacy and Safety of SZC in Patients with HFrEF Receiving Spironolactone Harriette Van Spall, Mikhail Kosiborod
-
6m 17sPart 3 | Session 1 LIBerate-OLE: Long-Term Efficacy of Lerodalcibep in Patients at High Risk for CVD Dean J Kereiakes
-
3m 53sPart 3 | Session 2 LIBerate-HeFH_OLE: Lerodalcibep in Heterozygous Familial Hypercholesterolemia Frederick Raal
-
7m 19sPart 3 | Session 3 Mavacamten: Real-World Experience from 22 Months of the REMS Program Milind Y Desai
-
10m 31sPart 3 | Session 4 VALOR-HCM: Mavacamten in Patients with Obstructive HCM Referred for Septal Reduction Therapy Milind Y Desai
-
4m 41sPart 3 | Session 5 EMPEROR-Preserved: Diastolic Dysfunction and Empagliflozin in Heart Failure Andrew JS Coats
-
6m 53sPart 3 | Session 6 Amulet IDE: The AMPLATZER Amulet Left Atrial Appendage Occluder Five-Year Results Dhanunjaya Lakkireddy
-
5m 6sPart 3 | Session 7 NTLA-2001 in Patients with Transthyretin Amyloidosis with Cardiomyopathy Marianna Fontana
Overview
Keep up-to-date with our video collection covering the American Heart Association's 2024 Scientific Sessions in Chicago. For expert insights on the hottest late-breaking and featured science trials, tune in to our collection.
- To catch reviews on the most awaited trials, watch our recurring series View From the ThoraxCenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL).
- Watch out for the Late-Breaker Discussions with Dr Harriette Van Spall for key clinical trial data and its implications for future research.
- Our concise Expert Interviews provide key data, study designs and take-home messages from select faculty.
- Don't miss the key take aways from our Highlights series.
More from this programme
Part 1
View From the Thoraxcenter
Part 2
Late-Breaker Discussions with Dr Harriette Van Spall
Part 3
Expert Interviews
Part 4
Highlights
About the episode
AHA Conference 2024 - Outcomes of SELECT show that semaglutide treatment in obese or overweight patients with prior history of coronary artery bypass graft (CABG) surgery reduces the risk of cardiovascular events.
Dr Subodh Verma (University of Toronto, Toronto, CA) joins us onsite at AHA Conference to discuss the findings from SELECT (NCT03574597).
SELECT is a randomized, double-blind, placebo-controlled, phase 3 trial investigating the use of semaglutide compared to placebo in obese or overweight patients with prior history of cardiovascular disease, including those with prior history of CABG. 17,604 patients were enrolled in the trial and were followed up from randomization up to 240 weeks. The primary outcome measure was the number of participants with first occurrence of a composite outcome measure consisting of non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death.
Interview Questions:
1. What is the reasoning behind the trial and current research landscape for semaglutide treatment?
2. What was the study design and patient population?
3. What were the key findings?
4. What are the take-home messages for practice?
5. What further research is needed in this area?
Recorded on-site at AHA Conference in Chicago, 2024.
Editors: Yazmin Sadik, Jordan Rance.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David Ben-Harosh.
Support: This is an independent interview produced by Radcliffe CVRM.
Faculty Biographies
Subodh Verma
Dr Subodh Verma is a cardiac surgeon-scientist at St Michael’s Hospital and Professor in the Departments of Surgery, and Pharmacology and Toxicity at the University of Toronto. He is also the current Canada Research Chair in Cardiovascular Surgery.
Dr Verma oversees a prolific basic, translational and clinical research program. He spearheads the CARDIOLINK clinical trials platform at St Michael’s Hospital and has leadership roles in seven ongoing global heart failure trials.
Comments